Previous Close | 135.30 |
Open | 140.15 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 140.15 - 140.15 |
52 Week Range | 118.16 - 153.10 |
Volume | |
Avg. Volume | 3,025 |
Market Cap | 217.263B |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | 36.78 |
EPS (TTM) | 3.81 |
Earnings Date | N/A |
Forward Dividend & Yield | 2.86 (2.04%) |
Ex-Dividend Date | Feb 22, 2024 |
1y Target Est | N/A |
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.
J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.